A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system

Drug Metabolism and Disposition

Volumn 35, Issue 1, 2007, Pages 67-71

  Lee, Su Jun ^a,c   Van Der Heiden, Ilse P ^b   Goldstein, Joyce A ^a   Van Schaik, Ron H N ^b  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Inje University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A5; NIFEDIPINE;

ARTICLE; DRUG METABOLISM; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALLELES; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; GENOTYPE; HUMANS; NIFEDIPINE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS;

ESCHERICHIA COLI;

EID: 33845953716     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.012310     Document Type: Article

References (39)

1. Barnes HJ, Arlotto MP, and Waterman MR (1991) Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in Escherichia coli. Proc Natl Acad Sci USA 88:5597-5601.
2. Chou FC, Tzeng SJ, and Huang JD (2001) Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab Dispos 29:1205-1209.
3. Domanski TL, He YA, Harlow GR, and Halpert JR (2000) Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity. J Pharmacol Exp Ther 293:585-591.
4. Domanski TL, Liu J, Harlow GR, and Halpert JR (1998) Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and alpha-naphthoflavone stimulation. Arch Biochem Biophys 350:223-232.
5. Goto M, Masuda S, Kiuchi T, Ogura Y, Oike F, Okuda M, Tanaka K, and Inui K (2004) CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 14:471-478.
6. Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1-17.
7. Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK, Watkins PB, and Hall SD (1996) Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 50:52-59.
8. Harlow GR and Halpert JR (1997) Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P450 3A4. Role of residues 210 and 211 in flavonoid activation and substrate specificity. J Biol Chem 272:5396-5402.
9. Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, and Wallemacq P (2004) The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14:147-154.
10. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, and van Gelder T (2003) Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74:245-254.
11. Huang Z, Fasco MJ, Figge HL, Keyomarsi K, and Kaminsky LS (1996) Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos 24:899-905.
12. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, et al. (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773-779.
13. Janardan SK, Lown KS, Schmiedlin-Ren P, Thummel KE, and Watkins PB (1996) Selective expression of CYP3A5 and not CYP3A4 in human blood. Pharmacogenetics 6:379-385.
14. Jounaidi Y, Hyrailles V, Gervot L, and Maurel P (1996) Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein? Biochem Biophys Res Commun 221:466-470.
15. Kivisto KT, Griese EU, Fritz P, Linder A, Hakkola J, Raunio H, Beaune P, and Kroemer HK (1996) Expression of cytochrome P 450 3A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours. Naunyn-Schmiedeberg's Arch Pharmacol 353:207-212.
16. Kivisto KT, Niemi M, Schaeffeler E, Pitkala K, Tilvis R, Fromm MF, Schwab M, Eichelbaum M, and Strandberg T (2004) Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 14:523-525.
17. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM, and Watkins PB (1994) CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247-259.
18. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, and Watkins PB (1992) Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Investig 90:1871-1878.
19. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
20. Lamba JK, Lin YS, Schuetz EG, and Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294.
21. Lee SJ, Bell DA, Coulter S, Ghanayem B, and Goldstein JA (2005) Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3 representing a new putative defective CYP3A haplotype. J Pharmacol Exp Ther 313:302-309.
22. Lee SJ and Goldstein JA (2005) Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics 6:357-371.
23. Lee SJ, Usmani KA, Chanas B, Ghanayem B, Xi T, Hodgson E, Mohrenweiser HW, and Goldstein JA (2003) Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 13:461-472.
24. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, and Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162-172.
25. Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83-448.
26. Saeki M, Saito Y, Nakamura T, Murayama N, Kim SR, Ozawa S, Komamura K, Ueno K, Kamakura S, Nakajima T, et al. (2003) Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Hum Mutat 21:653.
27. Schuetz EG, Schuetz JD, Grogan WM, Naray-Fejes-Toth A, Fejes-Toth G, Raucy J, Guzelian P, Gionela K, and Watlington CO (1992) Expression of cytochrome P450 3A in amphibian, rat, and human kidney. Arch Biochem Biophys 294:206-214.
28. Scott EE and Halpert JR (2005) Structures of cytochrome P450 3A4. Trends Biochem Sci 30:5-7.
29. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
30. Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, Ihrie P, Mehall JM, Edwards TL, and Dawson EP (2004) Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 5:895-931.
31. Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, Legendre C, and Daly AK (2003) Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76:1233-1253.
32. Thummel KE and Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430.
33. van Schaik RH, van der Heiden IP, van den Anker JN, and Lindemans J (2002) CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 48:1668-1671.
34. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, and Guzelian PS (1987) Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Investig 80:1029-1036.
35. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, and Ingelman-Sundberg M (2003) Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31:755-761.
36. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, and Wrighton SA (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30:883-891.
37. Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ, and Jhoti H (2004) Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science (Wash DC) 305:683-686.
38. Wong M, Balleine RL, Collins M, Liddle C, Clarke CL, and Gurney H (2004) CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther 75:529-538.
39. Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, and Johnson EF (2004) The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J Biol Chem 279:38091- 38094.